Cynata Therapeutics Ltd News

Cynata Therapeutics Ltd: Investor Webinar

Aug 30 12:34

Cynata Therapeutics Ltd: Appendix 4G

Aug 29 16:07

Cynata Therapeutics Ltd: Corporate Governance Statement

Aug 29 16:07

Cynata Therapeutics Ltd: Appendix 3Y - Dr Kilian Kelly

Aug 19 06:27

Cynata Therapeutics Ltd: Study of Cymerus MSCs in Pulmonary Fibrosis Published

Aug 8 07:49

Cynata Therapeutics Ltd: Quarterly Activity Report & Appendix 4C

Jul 30 06:40

Cynata Therapeutics Ltd: Cynata to Acquire IP from Tekcyte

Jul 1 07:49

Cynata Therapeutics Ltd: Further GvHD Clinical Data Published in Nature Medicine

May 22 17:10

Cynata Therapeutics Ltd: Appendix 3Y-Dr Geoffrey Brooke

May 17 06:26

Cynata Therapeutics Ltd: Quarterly Activity Report & Appendix 4C

Apr 30 06:54

Cynata Therapeutics Ltd: DFU Clinical Trial Enrolment Complete

Apr 8 06:58

Cynata Therapeutics Ltd: EU Approval for Phase 2 CYP-001 Trial in GvHD

Mar 20 05:55

Cynata Therapeutics Ltd: First Patient Treated in Phase 2 GvHD Trial

Mar 5 05:54

Cynata Therapeutics Ltd: Cynata Appoints New Chief Business Officer

Feb 29 06:19

Cynata Therapeutics Ltd: Encouraging Initial Data from CYP-006TK DFU Trial

Feb 26 06:01

Cynata Therapeutics Ltd: Quarterly Activity Report & Appendix 4C

Jan 30 05:56

Cynata Therapeutics Ltd: Initial Results in First 16 DFU Patients Expected in Q1 2024

Dec 28, 2023 05:52

Cynata Therapeutics Ltd: Recruitment Completed in Phase 3 OA Clinical Trial

Dec 13, 2023 06:46

Cynata Therapeutics Ltd: Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

Dec 7, 2023 06:39

Cynata Therapeutics Ltd: Appendix 3Y - Dr Kilian Kelly

Nov 23, 2023 06:13